1-3 of 3
Jan S. Rosenbaum
Close
Sort by
Journal Articles

Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients

Jan S. Rosenbaum, Amal S. Kolt, Scott B. Hoyt, Gregory M. Hayes, Brandi L. Soldo, Craig J. Thomas, Daniel T. Starczynowski
Journal: Blood
Blood (2023) 142 (Supplement 1): 4152.
https://doi.org/10.1182/blood-2023-189899
Published: 2023
Journal Articles

Inhibition of Both IRAK1 and IRAK4 Is Required for Complete Suppression of NF-Kb Signaling across Multiple Receptor-Mediated Pathways in MDS and AML

Jan S Rosenbaum, Scott B. Hoyt, Amal S. Kolt, Daniel A Luedtke, Craig J. Thomas, Daniel T. Starczynowski
Journal: Blood
Blood (2022) 140 (Supplement 1): 5949–5950.
https://doi.org/10.1182/blood-2022-167783
Published: 2022
Journal Articles

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Katelyn M. Melgar, PhD, LaQuita M Jones, DO, Mackenzie Walker, Lyndsey C Bolanos, BSc, Kathleen Hueneman, Mark Wunderlich, MS, Jiang-Kang Jiang, Kelli Wilson, Xiaohu Zhang, Patrick Sutter, Xin Xu, Kwangmin Choi, PhD, Gregory Tawa, Donald Lorimer, Jan Abendroth, Eric O'Brien, BSc, Scott Hoyt, Ellin Berman, MD, Christopher Famulare, MS, James C Mulloy, Ross L. Levine, MD, Jan S Rosenbaum, John P Perentesis, Craig J Thomas, PhD, Daniel T. Starczynowski, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3934.
https://doi.org/10.1182/blood-2019-124178
Published: 2019